- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06101095
Une étude évaluant la fonction œsophagienne et le remodelage avec le dupilumab par rapport au placebo pendant 24 semaines, suivis de 104 semaines en ouvert chez des participants adultes atteints d'EoE (REMOdeling avec dupilumab dans un essai à long terme sur l'œsophagite à éosinophiles)
Une étude de phase 4, randomisée, multicentrique, en double aveugle, en groupes parallèles, de 24 semaines, contrôlée par placebo, suivie de 104 semaines en ouvert pour évaluer l'efficacité du dupilumab sur la fonction œsophagienne et le remodelage chez les participants adultes atteints d'œsophagite à éosinophiles (EoE)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
Duration of study period (per participant)
- Screening period: Up to 12 weeks before Week 0
- Randomized double-blind period: 24 weeks
- Open label period: 104 weeks
- Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first.
There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The duration per participant will be up to 152 weeks.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
São Paulo, Brésil, 01323-020
- Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brésil, 41825-010
- Itaigara Memorial - Hospital Dia- Site Number : 0760005
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
-
-
São Paulo
-
Campinas, São Paulo, Brésil, 13010-001
- Clínica Loema - Unidade I- Site Number : 0760007
-
Sorocaba, São Paulo, Brésil, 18040-425
- Clinica de Alergia Martti Antila- Site Number : 0760001
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Investigational Site Number : 1240006
-
Vancouver, British Columbia, Canada, V6Z 2K5
- Investigational Site Number : 1240004
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3T2
- Investigational Site Number : 1240002
-
-
-
-
-
Haifa, Israël, 3104802
- Investigational Site Number : 3760006
-
Haifa, Israël, 3109601
- Investigational Site Number : 3760002
-
Jerusalem, Israël, 9103102
- Investigational Site Number : 3760005
-
Jerusalem, Israël, 9112001
- Investigational Site Number : 3760004
-
Tel Aviv, Israël, 6423906
- Investigational Site Number : 3760003
-
-
-
-
-
Wetzikon, Suisse, 8620
- Investigational Site Number : 7560001
-
Zurich, Suisse, 8091
- Investigational Site Number : 7560002
-
-
-
-
California
-
Murrieta, California, États-Unis, 92563
- United Gastroenterologists - Murrieta- Site Number : 8400001
-
San Francisco, California, États-Unis, 94143
- University of California San Francisco - Parnassus Heights- Site Number : 8400020
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32256
- Borland Groover Clinic- Site Number : 8400016
-
-
Idaho
-
Boise, Idaho, États-Unis, 83706
- Treasure Valley Medical Research- Site Number : 8400018
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University- Site Number : 8400003
-
Glenview, Illinois, États-Unis, 60026
- GI Alliance - Glenview- Site Number : 8400012
-
Gurnee, Illinois, États-Unis, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa- Site Number : 8400006
-
-
Massachusetts
-
Worcester, Massachusetts, États-Unis, 01655
- University of Massachusetts Chan Medical School- Site Number : 8400019
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic Hospital Rochester- Site Number : 8400008
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- University of North Carolina at Chapel Hill- Site Number : 8400007
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic - Cleveland- Site Number : 8400009
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
-
-
Texas
-
Houston, Texas, États-Unis, 77087
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015
-
Mansfield, Texas, États-Unis, 76063
- GI Alliance - Mansfield- Site Number : 8400017
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- A documented diagnosis of EoE by endoscopic biopsy.
- Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration.
- History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.
- Body weight ≥40 kg.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome).
- Active Helicobacter pylori infection.
- History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery.
- Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening.
- History of bleeding disorders or esophageal varices.
- Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline.
- Initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening.
- Participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or contraindicated to dupilumab per local labelling.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
SC injection as per protocol |
SC injection as per protocol |
|
Expérimental: Dupilumab
Subcutaneous injection (SC) as per protocol |
Subcutaneous injection (SC) as per protocol |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
Délai: From baseline to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline to Week 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence des événements indésirables survenus pendant le traitement (TEAE) et des événements indésirables graves (EIG)
Délai: De la première administration d'IMP jusqu'à la fin de la période de suivi post-traitement (semaine 139)
|
De la première administration d'IMP jusqu'à la fin de la période de suivi post-traitement (semaine 139)
|
|
|
Incidence des événements indésirables d'intérêt particulier (AESI)
Délai: De la première administration d'IMP jusqu'à la fin de la période de suivi post-traitement (semaine 139)
|
De la première administration d'IMP jusqu'à la fin de la période de suivi post-traitement (semaine 139)
|
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Délai: From baseline up to Week 24
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week 24
|
|
Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Délai: From baseline up to Week128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From baseline up to Week128
|
|
Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Délai: From Baseline up to Week 128
|
Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function. |
From Baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis-endoscopic reference score (EoE-EREFS)
Délai: From baseline up to Week 128
|
EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease. |
From baseline up to Week 128
|
|
Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade
Délai: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Change from baseline in EoE-HSS Stage
Délai: From Baseline up to Week 128
|
Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities. |
From Baseline up to Week 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤6 eosinophils/high power field (Eos/HPF)
Délai: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPF
Délai: At Week 24
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Week 24
|
|
Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPF
Délai: At Weeks 24, 76 and 128
|
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). |
At Weeks 24, 76 and 128
|
|
Change from baseline in normalized enrichment score (NES) for EoE diagnostic panel (EDP) transcriptome signature
Délai: From baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From baseline up to Week 128 (EOT)
|
|
Change from baseline in normalized enrichment score (NES) for type 2 inflammation transcriptome signature
Délai: From Baseline up to Week 128 (EOT)
|
NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease). |
From Baseline up to Week 128 (EOT)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Clinical Sciences & Operations, Sanofi
Publications et liens utiles
Publications générales
- Dellon ES, Carlson DA, Greuter T, Collins MH, Lankarani A, Talreja N, Ravi K, Simoes Neto J, Afif W, Gonsalves NP, Lynch KL, Zaghloul S, Cunoosamy D, Durrani SR, Zhang M, Raphael BP, Angello JT, Radwan A, Almansa C, Biedermann L. Dupilumab Improves Esophageal Distensibility in EoE: 24-Week Results From the REMODEL Randomized Trial. Am J Gastroenterol. 2026 Oct 12. doi: 10.14309/ajg.0000000000004227. Online ahead of print.
- Dellon ES, Savarino EV, Zaghloul S, Angello JT, Zhang M, Raphael BP, Radwan A, Bredenoord AJ. Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial. Ther Adv Gastroenterol. 2025 Oct 9;18:17562848251383782. doi: 10.1177/17562848251383782. eCollection 2025.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Maladies du système digestif
- Maladies gastro-intestinales
- Hypersensibilité immédiate
- Hypersensibilité
- Éosinophilie
- Troubles leucocytaires
- Maladies hématologiques
- Maladies de l'oesophage
- Gastro-entérite
- Oesophagite
- Maladies hémiques et lymphatiques
- Oesophagite à éosinophiles
- dupulumab
Autres numéros d'identification d'étude
- LPS17558
- U1111-1280-5266 (Identificateur de registre: ICTRP)
- 2022-502491-23 (Identificateur de registre: CTIS)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .